Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study

References

Page 1

	Year	Citations
Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate Andrew S. Levey, Josef Coresh, Tom Greene, Annals of Internal Medicine	2006	5.7K
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection Nezam H. Afdhal, Stefan Zeuzem, Paul Y. Kwo, New England Journal of Medicine	2014	1.7K
Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study Juliette Foucher Gut	2005	1.3K
Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection John G. McHutchison, Eric Lawitz, Mitchell L. Shiffman, New England Journal of Medicine	2009	1.2K
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis Kris V. Kowdley, Stuart C. Gordon, K. Rajender Reddy, New England Journal of Medicine	2014	1.1K
Comparative analysis of two rates Olli S. Miettinen, Markku Nurminen Statistics in Medicine EngineeringComparative TestStatistical FoundationRate RatioMathematical Statistic	1985	1.1K
Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection Stefan Zeuzem, Reem Ghalib, K. Rajender Reddy, Annals of Internal Medicine	2015	514
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial Eric Lawitz, Edward Gane, Brian L. Pearlman, The Lancet Open-label Phase 2HepatologyHepatitis CViral HepatitisPrevious Null Response	2014	299
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial Mark Sulkowski, Christophe Hézode, Jan Gerstoft, The Lancet Open-label Phase 2Hepatitis CViral HepatitisAntiviral Drug DevelopmentAntiviral Therapy	2014	279
HARMFUL LONG-TERM IMPACT OF HEPATITIS C VIRUS INFECTION IN KIDNEY TRANSPLANT RECIPIENTS C. Legendre, Valérie Garrigue, Christine Le Bihan-Benjamin, Transplantation	1998	258

Page 1